Geode Capital Management LLC Has $3.81 Million Position in Gyre Therapeutics, Inc. (NASDAQ:GYRE)

Geode Capital Management LLC grew its position in shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) by 16.9% during the third quarter, HoldingsChannel.com reports. The firm owned 303,647 shares of the company’s stock after purchasing an additional 43,840 shares during the period. Geode Capital Management LLC’s holdings in Gyre Therapeutics were worth $3,808,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. FMR LLC acquired a new stake in Gyre Therapeutics during the 3rd quarter worth approximately $47,000. Barclays PLC raised its stake in shares of Gyre Therapeutics by 281.8% during the third quarter. Barclays PLC now owns 9,288 shares of the company’s stock valued at $116,000 after acquiring an additional 6,855 shares during the last quarter. Rhumbline Advisers acquired a new position in shares of Gyre Therapeutics during the second quarter worth $123,000. Renaissance Technologies LLC bought a new stake in shares of Gyre Therapeutics in the second quarter worth $166,000. Finally, Bank of New York Mellon Corp acquired a new stake in Gyre Therapeutics in the second quarter valued at $218,000. 23.99% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, President Songjiang Ma sold 2,000 shares of the business’s stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $12.70, for a total value of $25,400.00. Following the transaction, the president now owns 2,928,467 shares in the company, valued at $37,191,530.90. The trade was a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold a total of 12,000 shares of company stock valued at $143,480 over the last ninety days. 19.52% of the stock is owned by company insiders.

Gyre Therapeutics Stock Down 9.8 %

Shares of GYRE opened at $9.73 on Tuesday. The stock’s 50-day moving average price is $12.40 and its two-hundred day moving average price is $12.68. Gyre Therapeutics, Inc. has a 12 month low of $8.26 and a 12 month high of $27.10.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.